Testing stem cell transplant in higher-risk myelodysplastic syndrome
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 3 trial tests whether doing an “allogeneic” stem cell transplant works best for people newly diagnosed with higher-risk MDS (a bone marrow disorder). It’s mainly for patients who are healthy enough to receive a transplant and haven’t started MDS treatment yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a new diagnosis of higher-risk MDS (not previously treated for this).
- You are between 18 and 70 years old.
- A specialist says you are eligible to receive a stem cell transplant.
- You have enough general health to do daily activities (performance status 0–2).
- You are expected to live at least 3 months, and you can sign consent.
- You do NOT have AML with more than 20% abnormal cells in blood or bone marrow, and you don’t have certain other serious conditions (like major organ disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special conditioning regimen (VA) before a stem cell transplant for older patients with higher-risk myelodysplastic syndrome (MDS). It aims to make the transplant safer and more effective for this group.
This study tests a combination of two drugs, azacitidine and rotercept, for people with a type of blood cancer called myelodysplastic syndrome (MDS) that has a higher risk of progressing. The goal is to see if adding rotercept helps control the disease better than standard care.
This trial tests a stem cell transplant that uses specially selected cells (CD34+ cells) to treat myelodysplastic syndrome (MDS), a blood disorder. The transplant comes from a donor and aims to replace unhealthy blood-forming cells with healthy ones, which may slow or stop the disease. It is designed for patients with higher-risk MDS or certain high-risk features.
This trial tests a type of stem cell transplant (using cells from a partially matched donor and umbilical cord blood) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to help patients whose disease is high-risk, has returned after treatment, or hasn't responded well to chemotherapy.
This trial tests a new drug, AK117, combined with azacitidine for people newly diagnosed with high-risk myelodysplastic syndromes (MDS), a blood disorder. The goal is to see if the combination can help improve outcomes.
This trial looks at using a family donor transplant right away for people with higher-risk myelodysplastic syndrome (MDS). The goal is to see if this early transplant is safe and helps control the disease.
Hear when a new High-risk MDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.